5 Small-Cap Stocks That Are On Fire Right Now

In this article, we will list the 5 Small-Cap Stocks That Are On Fire Right Now. Please visit 10 Small-Cap Stocks That Are On Fire Right Now to see the extended list and the methodology behind it.

5. Oruka Therapeutics (NASDAQ:ORKA)

Year-to-Date Performance: 149.38%

Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibody targeting moderate-to-severe plaque psoriasis. The study met its primary endpoint, with 63.5% of patients achieving complete skin clearance (PASI 100) by Week 16. These efficacy rates are numerically higher than those of other current IL-23p19 inhibitors, placing ORKA-001 among the top-performing treatments for this condition.

The safety profile for ORKA-001 remained favorable and consistent with its drug class, with no serious treatment-emergent adverse events reported in the treated group. Most side effects were mild, with upper respiratory tract infections being the only common event observed. Crucially, updated data from earlier phases suggest the drug maintains effective concentrations for an entire year after a single dose, reinforcing the potential for once-yearly dosing, an improvement over current treatment frequencies.

Following these results, Oruka Therapeutics (NASDAQ:ORKA) plans to release longer-term follow-up data, including 52-week results for a subset of patients, in H2 2026. The company is also moving forward with its EVERLAST-B Phase 2b trial, with data expected in 2027. If successful, ORKA-001 could redefine the standard of care by offering high-level skin clearance with substantially fewer injections than existing biologics.

Oruka Therapeutics (NASDAQ:ORKA) is a biopharmaceutical company developing next-generation biologics for chronic skin and inflammatory diseases. Its lead antibody programs target plaque psoriasis and psoriatic arthritis, aiming to provide complete disease clearance with maintenance dosing as infrequent as once or twice a year.